# US 2025/0145697 A1 · Anti-apoe antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145697 A1
- Document ID: US20250145697A1
- Status: Published application
- Kind: A1
- Application number: 18/942,122
- Filed: 2024-11-08
- Published: 2025-05-08
- Earliest claimed: 2016-10-28
- Assignees: Washington University
- Applicants: Washington University
- Inventors: David Holtzman; Hong Jiang; Thu Nga Bien-Ly; Mark S. Dennis; Jing Guo; Adam P. Silverman; Ryan J. Watts; Yin Zhang
- Web page: https://patentgrep.com/patent/US20250145697A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 2039/505: {comprising antibodies}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of Aβ plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.

## Claims

### Claim at position 1

-218. (canceled)

### Claim 219

An anti-ApoE4 antibody or antigen-binding fragment thereof, comprising a heavy chain variable domain comprising three complementarity determining regions (CDRs), wherein the heavy chain variable domain CDRs are CDR-H1, CDR-H2, and CDR-H3 according to Chothia numbering, and wherein
(i) the CDR-H1 comprises the amino acid sequence set forth at positions 26 to 32 of SEQ ID NO: 12;
(ii) the CDR-H2 comprises the amino acid sequence set forth at positions 54 to 56 of SEQ ID NO: 12; and
(iii) the CDR-H3 comprises the amino acid sequence set forth at positions 100 to 106 of SEQ ID NO: 12.

### Claim 220 (depends on 219)

The anti-ApoE4 antibody or antigen-binding fragment thereof of claim 219, which is a single-domain antibody (sdAb), heavy chain antibody, Fv, Fab, Fab′, Fab′-SH, F(ab′) 2, single-chain antibody (scAb), single chain variant fragment (scFv), divalent scFv (di-scFv), trivalent scFv (tri-scFv), tetravalent scFv (tetra-scFv), diabody, triabody, tetrabody, or full length antibody.

### Claim 221 (depends on 219)

The anti-ApoE4 antibody or antigen-binding fragment thereof of claim 219, which binds to ApoE4 and ApoE3.

### Claim 222 (depends on 219)

The anti-ApoE4 antibody or antigen-binding fragment thereof of claim 219, which binds to an epitope comprising amino acids 140-150 of mature ApoE.

### Claim 223 (depends on 219)

The anti-ApoE4 antibody or antigen-binding fragment thereof of claim 219, wherein the heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO:12.

### Claim 224 (depends on 219)

The anti-ApoE4 antibody or antigen-binding fragment thereof of claim 219, further comprising a light chain variable domain comprising three CDRs, wherein the light chain variable domain CDRs are CDR-L1, CDR-L2, and CDR-L3 according to Chothia numbering, and wherein
(i) the CDR-L1 comprises an amino acid sequence derived from the variable region amino acid sequence of SEQ ID NO:11, wherein the CDR-L1 comprises an amino acid sequence having one amino acid replacement substitution to the sequence set forth at positions 26 to 37 of SEQ ID NO:11;
(ii) the CDR-L2 comprises the amino acid sequence set forth at positions 55 to 57 of SEQ ID NO:11; and
(iii) the CDR-L3 comprises the amino acid sequence set forth at positions 96 to 101 of SEQ ID NO:11.

### Claim 225 (depends on 224)

The anti-ApoE4 antibody or antigen-binding fragment thereof of claim 224, which is a Fv, Fab, Fab′, Fab′-SH, F(ab′) 2, single-chain antibody (scAb), single chain variant fragment (scFv), divalent scFv (di-scFv), trivalent scFv (tri-scFv), tetravalent scFv (tetra-scFv), diabody, triabody, tetrabody, or full length antibody.

### Claim 226 (depends on 224)

The anti-ApoE4 antibody or antigen-binding fragment thereof of claim 224, comprising
(a) a first heavy chain variable domain and a second heavy chain variable domain, each comprising
(i) a CDR-H1 comprising the amino acid sequence set forth at positions 26 to 32 of SEQ ID NO: 12;
(ii) a CDR-H2 comprising the amino acid sequence set forth at positions 54 to 56 of SEQ ID NO:12; and
(iii) a CDR-H3 comprising the amino acid sequence set forth at positions 100 to 106 of SEQ ID NO:12, and
(b) a first light chain variable domain and a second light chain variable domain, each comprising
(i) a CDR-L1 comprising an amino acid sequence derived from the variable region amino acid sequence of SEQ ID NO:11, wherein the CDR-L1 comprises an amino acid sequence having one amino acid replacement substitution to the sequence set forth at positions 26 to 37 of SEQ ID NO:11;
(ii) a CDR-L2 comprising the amino acid sequence set forth at positions 55 to 57 of SEQ ID NO: 11; and
(iii) a CDR-L3 comprising the amino acid sequence set forth at positions 96 to 101 of SEQ ID NO:11.

### Claim 227 (depends on 224)

The anti-ApoE4 antibody or antigen-binding fragment thereof of claim 224, comprising
(a) a first heavy chain comprising a first heavy chain variable domain and a first heavy chain constant domain, and
a second heavy chain comprising a second heavy chain variable domain a second heavy chain constant domain,
wherein each of the first and second heavy chain variable domains comprise
(i) a CDR-H1 comprising the amino acid sequence set forth at positions 26 to 32 of SEQ ID NO:12;
(ii) a CDR-H2 comprising the amino acid sequence set forth at positions 54 to 56 of SEQ ID NO: 12; and
(iii) a CDR-H3 comprising the amino acid sequence set forth at positions 100 to 106 of SEQ ID NO:12, and
(b) a first light chain comprising a first light chain variable domain and a first light chain constant domain, and
a second light chain comprising a second light chain variable domain and a second light chain constant domain,
wherein each of the first and second light chain variable domains comprise
(i) a CDR-L1 comprising an amino acid sequence derived from the variable (i) region amino acid sequence of SEQ ID NO:11, wherein the CDR-L1 comprises an amino acid sequence having one amino acid replacement substitution to the sequence set forth at positions 26 to 37 of SEQ ID NO:11;
(ii) a CDR-L2 comprising the amino acid sequence set forth at positions 55 to 57 of SEQ ID NO: 11; and
(iii) a CDR-L3 comprising the amino acid sequence set forth at positions 96 to 101 of SEQ ID NO:11.

### Claim 228 (depends on 227)

The anti-ApoE4 antibody or antigen-binding fragment thereof of claim 227, wherein
(a) the first heavy chain constant domain and second heavy chain constant domain are human heavy chain constant domains, and
(b) the first light chain constant domain and second light chain constant domain are human light chain constant domains.

### Claim 229 (depends on 227)

The anti-ApoE4 antibody or antigen-binding fragment thereof of claim 227, wherein the first heavy chain and second heavy chain each comprise an Fc region.

### Claim 230 (depends on 228)

The anti-ApoE4 antibody or antigen-binding fragment thereof of claim 228, wherein the first heavy chain and second heavy chain each comprise an Fc region.

### Claim 231 (depends on 229)

The anti-ApoE4 antibody or antigen-binding fragment thereof of claim 229, wherein each of the Fc region of the first heavy chain and the Fc region of the second heavy chain each is a human Fc region.

### Claim 232 (depends on 230)

The anti-ApoE4 antibody or antigen-binding fragment thereof of claim 230, wherein each of the Fc region of the first heavy chain and the Fc region of the second heavy chain each is a human Fc region.

### Claim 233 (depends on 219)

The anti-ApoE4 antibody or antigen-binding fragment thereof of claim 219, which is a human or humanized IgG1 antibody.

### Claim 234 (depends on 224)

The anti-ApoE4 antibody or antigen-binding fragment thereof of claim 224, which is a human or humanized IgG1 antibody.

### Claim 235 (depends on 226)

The anti-ApoE4 antibody or antigen-binding fragment thereof of claim 226, which is a human or humanized IgG1 antibody.

### Claim 236 (depends on 227)

The anti-ApoE4 antibody or antigen-binding fragment thereof of claim 227, which is a human or humanized IgG1 antibody.

### Claim 237 (depends on 219)

A nucleic acid, encoding the anti-ApoE4 antibody or antigen-binding fragment thereof of claim 219.

### Claim 238 (depends on 237)

A vector, comprising the nucleic acid of claim 237.

### Claim 239

An anti-ApoE4 antibody or antigen-binding fragment thereof, comprising (a) a light chain variable domain comprising three complementarity determining regions (CDRs), wherein the light chain variable domain CDRs are CDR-L1, CDR-L2, and CDR-L3 according to Chothia numbering and (b) a heavy chain variable domain comprising three CDRs, wherein the heavy chain variable domain CDRs are CDR-H1, CDR-H2, and CDR-H3 according to Chothia numbering, and wherein
(i) the CDR-H1 comprises the amino acid sequence set forth at positions 26 to 32 of SEQ ID NO: 12;
(ii) the CDR-H2 comprises the amino acid sequence set forth at positions 54 to 56 of SEQ ID NO: 12; and
(iii) the CDR-H3 comprises the amino acid sequence set forth at positions 100 to 106 of SEQ ID NO:12.
